Navigation Links
Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
Date:2/11/2009

COLUMBIA, S.C., Feb. 11 /PRNewswire/ -- Welvista is pleased to announce it has reached an agreement with Takeda to dispense a selection of the company's medications to the uninsured through Welvista's no-cost prescription medication program. With the addition of six Takeda products, Welvista now has 213 drugs on its formulary for the uninsured. Including Takeda, Welvista now partners with 12 pharmaceutical companies, making it the largest mail-order pharmacy for the uninsured in the country.

Welvista provides an innovative prescription drug program for residents in South Carolina and Texas who fall below 200 percent of the federal poverty level and are without health insurance coverage. The William E. Murray pharmacy, located at Welvista's headquarters off Forest Drive in Columbia, dispensed more than $34.5 million dollars in prescription medications in 2008 to Welvista's patients to treat diabetes, hypertension, mental illness and more.

Welvista also provides oral healthcare services for the children of limited income families in South Carolina through Smiles for a Lifetime, with centers in Allendale County, Dillon II, and Clarendon I and II school districts, and Charleston.

"We are excited to have Takeda as our newest pharmaceutical partner. We couldn't exist without our generous partners," says Welvista CEO Ken Trogdon. "We are committed to improving health and wellness for the uninsured. Our model has proven its viability and we will continue to add prescription drugs that we know our patients need."

About Welvista

Welvista is an innovative model of non-governmental healthcare intervention serving thousands of patients in SC and Texas. This healthcare network provides medications at no cost to the uninsured who do not qualify for Medicaid, Medicare or VA insurance and those who cannot afford to pay for insurance coverage on their own. Welvista also operates Smiles, five pediatric dental care centers caring for approximately 3,200 children from limited income families who would not otherwise have access to oral healthcare. With the addition of Takeda, Welvista now partners with 12 pharmaceutical companies that donate prescription drugs to approved patients. To learn more about the organization, visit www.welvista.org.

About Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Illinois, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Welvista
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
2. ActivCore LLC Announces Strategic Partnership with Wellness in Motion
3. Sensiotec Announces FDA 510(k) Class II Clearance for the Worlds First UWB Healthcare Unbound, Wireless, Non-Contact, Vital Signs and Movement Monitor
4. TheWrap.Com Announces MPTF is Responding to Media Investigation
5. Hillenbrand Announces Dividend of $0.185 Per Share
6. China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results
7. HCA Announces Offering of $300 Million Senior Secured Second Lien Notes
8. Triple-S Management Corporation Announces Delay in Reporting Fourth-Quarter And Year-End Results
9. The Network Journal Announces it's 2009 List of "25 Influential Black Women in Business"
10. Prison Health Services, Inc. Announces Contract for Prisoner Health Care Services With the State of Michigan Department of Corrections
11. NBTY Announces Preliminary Unaudited Net Sales Results for January 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New Jersey ... as well as advocacy for the state and region‘s technology businesses, hosted their ... The Council's Innovation Forecast event highlights innovation throughout the region from small to ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology: